Assessment, triage, and chemoembolization for colorectal liver metastases

doi:10.1017/CBO9781107338555.017

17 - Assessment, triage, and chemoembolization for colorectal liver metastases

from Section IV - Organ-specific cancers – liver metastases

Published online by Cambridge University Press: 05 September 2016

Michael C. Soulen ,

Govindarajan Narayanan and

Ursina Teitelbaum

Edited by

Jean-Francois H. Geschwind and

Michael C. Soulen

Show author details

Michael C. Soulen: Affiliation:
University of Pennsylvania
Govindarajan Narayanan: Affiliation:
University of Miami
Ursina Teitelbaum: Affiliation:
University of Pennsylvania
Jean-Francois H. Geschwind: Affiliation:
Yale University School of Medicine, Connecticut
Michael C. Soulen: Affiliation:
Department of Radiology, University of Pennsylvania Hospital, Philadelphia

Book contents

Get access

Summary

The prognosis of patients with colorectal carcinoma rests largely on the presence or absence of distant metastases. In 2013, there were an estimated 142,820 new cases of colon cancer in the USA, with a prevalence of over 1.1 million and 50,830 annual deaths from the disease. Twenty percent of newly diagnosed patients already have metastases, and many more develop metastatic disease over time. The liver is the first and most common site, with 80% of stage IV patients having liver involvement and 40% of patients dying with the liver as their only site of metastases. Among patients with extrahepatic disease, more than half still die from liver failure. Resection of liver metastases improves long-term survival; however, for the 75% of patients who are not resectable, palliative treatments to delay cancer progression to fatal liver failure is the standard of care.

Assessment of the patient with liver metastases

Initial assessment of the patient with colorectal liver metastases incorporates the history and physical examination, review of laboratory studies including tumor markers, diagnostic imaging, and pathology. Performance status is an important prognostic factor, since patients with declining function (Eastern Cooperative Oncology Group (ECOG) > 2) tend not to benefit from liver-directed therapies despite being otherwise eligible to receive them.

High-quality anatomic and functional imaging is key for treatment planning and subsequent response assessment. Reports of diagnostic imaging studies alone do not provide the level of detail needed for triage and treatment planning. The interventional oncologist should carefully review anatomic imaging (computed tomography (CT) or magnetic resonance imaging (MRI)) to assess segmental tumor burden. The first question to answer is if the patient is resectable, or could be converted to resectability through multidisciplinary interventions such as downstaging, ablation, or portal vein embolization. Close collaboration with a surgical oncologist can lead to potentially curative treatment plans even for multifocal disease. For unresectable disease, analysis of the size, location, and distribution of metastases in the liver will guide treatment planning among ablation and embolotherapies. High-quality imaging also depicts classical or variant arterial anatomy, status of the bile ducts and portal veins, and presence of ascites or extrahepatic disease. Positron emission tomography (PET)-CT shows fluorodeoxyglucose (FDG)-avidity in the majority of patients with metastatic colorectal cancer and can be helpful in following treatment response for therapies where conventional Response Evaluation Criteria In Solid Tumors (RECIST) imaging is less useful, such as ablation and embolization.

Information

Type: Chapter
Information: Interventional Oncology
Principles and Practice of Image-Guided Cancer Therapy
, pp. 148 - 157

DOI: https://doi.org/10.1017/CBO9781107338555.017 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

1. Steinberg, SM, Barkin, JS, Kaplan, RS, et al. Prognostic indicators of colon tumors: The Gastrointestinal Tumor Study Group experience. Cancer 1986; 57 (9): 1866–1870.Google Scholar

2. Chafai, N, Chan, CL, Bokey, El, et al. What factors influence survival in patients with unresected synchronous liver metastases after resection of colorectal cancer? Colorectal Dis 2005; 7 (2): 176–181.Google Scholar

3. Stangl, R, Altendorf-Hofmann, A, Charnley, RM, et al. Factors influencing the natural history of colorectal liver metastases. Lancet 1994; 343: 1405–1410.Google Scholar

4. SEER Stat Fact Sheets; Colon and Rectum Cancer. seer.cancer.gov/statfacts/html/colorect/html (accessed 1/25/14).

5. Frankel, TL, D'Angelica, MI. Hepatic resection for colorectal metastases. J Surg Oncol 2014; 109: 2–7.Google Scholar

6. Wagner, JS, Adson, MA, Heerden, JA Van, et al. The natural history of hepatic metastases from colorectal cancer: A comparison with resective treatment. Ann Surg 1984; 199: 502–508.Google Scholar

7. Mayo, SC, Pawlik, TM. Current management of colorectal hepatic metastasis. Expert Rev Gastroenterol Hepatol 2009; 3: 131–144.Google Scholar

8. Tan, MC, Butte, JM, Gonen, M, et al. Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastases. HPB 2013; 15: 808–813.Google Scholar

9. Tuite, CM, Sun, W, Soulen, MC. General assessment of the patient with cancer for the interventional oncologist. J Vasc Interv Radiol 2006; 17: 753–758.Google Scholar

10. Jong, MC de, Pulitano, C, Ribero, D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: An international multi-institutional analysis of 1669 patients. Ann Surg 2009; 250 (3): 440–448. PubMed PMID: 19730175Google Scholar

11. Shindoh, J, Tzeng, CW, Aloia, TA, et al. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol 2013; 20: 2493–2500.Google Scholar

12. Gillams, AR, Lees, WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 2009; 19: 1206–1213. PMID 19137310Google Scholar

13. Benson, AB III, Bekali-Saab, T, Chan, E, et al. Metastatic colon cancer, version 3.2013: Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2013; 11: 141–152.Google Scholar

14. Aprile, G, Lutrino, SE, Ferrari, L, et al. Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. World J Gastroenterol 2013; 19: 8474–8488.Google Scholar

15. Macedo, LT, Costa Lima, AB de, Sasse, AD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: A systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer 2012; 12: 89.Google Scholar

16. Peeters, M, Cohn, A, Kohne, CH, Douillard, JY. Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma. Clin Colorectal Cancer 2012; 11: 14–23.Google Scholar

17. Power, DG, Kemeny, NE. The role of floxuridine in metastatic liver disease. Mol Cancer Ther 2009; 8: 1015–1025.Google Scholar

18. Nanshima, A, Takeshita, H, Abo, T, et al. Recent advances and significance of intra-arterial infusion chemotherapy in non-resectable colorectal liver metastases. J Gastrointest Oncol 2013; 4: 164–172.Google Scholar

19. Nakamura, H, Hashimoto, T, Oi, H, et al. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989; 170: 783–786.Google Scholar

20. Sasaki, Y, Imaoka, S, Kasugai, H, et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 1987; 60: 1194–1203.Google Scholar

21. Konno, T. Targeting cancer chemotherapeutic agents by use of Lipiodol contrast medium. Cancer 1990; 66: 1897–1903.Google Scholar

22. Egawa, H, Maki, A, Mori, K, et al. Effects of intra-arterial chemotherapy with a new lipophilic anticancer agent, estradiol-chlorambucil (KM2210), dissolved in Lipiodol on experimental liver tumor in rats. J Surg Oncol 1990; 44 (2): 109–114.Google Scholar

23. Kruskal, JB, Hlatky, L, Hahnfeldt, P, et al. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol 1993; 4 (6): 741–747.Google Scholar

24. Ramsey, DE, Kernagis, LY, Soulen, MC, et al. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002; 13 (9): S211–S221.Google Scholar

25. Li, X, Feng, GS, Zheng, CS, et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004; 10 (19): 2878–2882.Google Scholar

26. Liao, X, Yi, J, Li, X, et al. Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial chemoembolization. J Huazhong Univ Sci Technol Med Sci 2003; 23 (3): 280–282.Google Scholar

27. Bujis, M, Reyes, DK, Pawlik, TM, et al. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2013; 119: 1042–1049.Google Scholar

28. Weintraub, JL, Salem, R. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: State of the science. J Vasc Intervent Radiol 2013; 24: 1123–1134.Google Scholar

29. Kamat, PP, Gupta, S, Ensor, JE, et al. Hepatic arterial embolization and chemoembolization in the management of patients with large-volume liver metastases. Cardiovasc Intervent Radiol 2008; 31: 299–307. PMID 17922160Google Scholar

30. Charnsangavej, C. Chemoembolization of liver tumors. Semin Invest Radiol 1993; 10: 150–160.Google Scholar

31. Pentecost, MJ, Daniels, JR, Teitelbaum, GP, et al. Hepatic chemoembolization: Safety with portal vein thrombosis. J Vasc Interv Radiol 1993; 4 (3): 347–351.Google Scholar

32. Kim, W, Clark, TWI, Baum, RA, et al. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12: 965–968.Google Scholar

33. Khan, W, Sullivan, KL, McCann, JW, et al. Moxifloxacin prophylaxis for chemoembolization or embolization in patients with prior biliary interventions: A pilot study. AJR 2011; 197: W343–W345.Google Scholar

34. Fong, ZV, Palazzo, F, Needleman, L, et al. Combined hepatic arterial embolization and hepatic ablation for unresectable colorectal metastases to the liver. Ann Surg 2012; 78: 1243–1248. PMID 23089443Google Scholar

35. Vogl, TJ, Gruber, T, Balzer, JO, et al. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: Prospective study. Radiology 2009; 250: 281–289.Google Scholar

36. Gaba, RC. Chemoembolization practice patterns and technical methods among interventional radiologists: Results of an online survey. AJR 2012; 198: 692–699.Google Scholar

37. Stuart, K. Chemoembolization in the management of liver tumors. Oncologist 2003; 8: 425–437.Google Scholar

38. Kan, Z, Ivancev, K, Hagerstrand, I, et al. In vivo microscopy of the liver after injection of Lipiodol into the hepatic artery and portal vein in the rat. Acta Radiol 1989; 30 (4): 419–425.Google Scholar

39. Kan, Z, Sato, M, Ivancev, I, et al. Distribution and effect of iodized poppyseed oil in the liver after hepatic artery embolization: Experimental study in several animal species. Radiology 1993; 186 (3): 861–866.Google Scholar

40. Kobayashi, H, Hidaka, H, Kajiya, Y, et al. Treatment of hepatocellular carcinoma by transarterial injection of anti-cancer agents in iodized oil suspension or of radioactive iodized oil solution. Acta Radiol Diagn 1986; 27 (2): 139–147.Google Scholar

41. Tellez, C, Benson, AB 3rd, Lyster, MT, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998; 82 (7): 1250–1259.Google Scholar

42. Solomon, B, Soulen, MC, Baum, RA, et al. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-c, ethiodol and polyvinyl alcohol: Prospective evaluation of response and survival in U.S. population. J Vasc Inter Radiol 1999; 10: 793–798.Google Scholar

43. Jordan, O, Denys, A, Baere, T de, et al. Comparative study of chemoembolization loadable beads: In vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan. J Vasc Interv Radiol 2010; 21: 1084–1090.Google Scholar

44. Rao, PP, Pascale, F, Seck, A, et al. Irinotecan loaded in eluting beads: Preclinical assessment in a rabbit VX2 liver tumor model. Cardiovasc Intervent Radiol 2012; 35: 1448–1459.Google Scholar

45. Liu, DM, Salem, R, Bui, JT, et al. Angiographic considerations in patients undergoing liver directed therapy. J Vasc Interv Radiol 2005; 16: 911–935.Google Scholar

46. Iwazawa, J, Ohue, S, Hashimoto, N, Muramoto, O, Mitani, T. Survival after C-arm CT-assisted chemoembolization of unresectable hepatocellular carcinoma. Eur J Radiol 2012; 81: 3985–3992.Google Scholar

47. Borner, M, Castiglione, M, Triller, J, et al. Considerable side effects of chemoembolization for colorectal carcinoma metastatic to the liver. Ann Oncol 1992; 3 (2): 113–115.Google Scholar

48. Leung, DA, Goin, JE, Sickles, C, et al. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12: 321–326.Google Scholar

49. Brown, DB, Cardella, JF, Sacks, D, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2009; 20: S219–S226.Google Scholar

50. Lewis, AL, Gonzalez, MV, Leppard, SW, et al. Doxorubicin eluting beads – 1: Effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med 2007; 18: 1691–1699.Google Scholar

51. Kaiser, J, Thiesen, J and Kramer, I. Stability of irinotecan-loaded drug eluting beads (DC Bead) used for transarterial chemoembolization. J Oncol Pharm Pract 2010; 16: 53–61.Google Scholar

52. Jones, RP, Dunne, D, Sutton, P, et al. Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: A case-control series. HPB (Oxford) 2013; 15: 71–77.Google Scholar

53. Fiorentini, G, Aliberti, C, Tilli, M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: Final results of a phase III study. Anticancer Res, 2012; 32: 1387–1395.Google Scholar

54. Martin, RC, Howard, J, Tomalty, D, et al.Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: Results of a multi-institutional registry. Cardiovasc Intervent Radiol 2010; 33: 960–966.Google Scholar

55. Daniels, S, Pentecost, M, Teitelbaum, G, et al. Hepatic artery chemoembolization for carcinoma of colon using angiostat collagen and cisplatin, mitomycin and doxorubicin: Response, survival and serum drug levels. Proc Am Soc Clin Oncol 1992; 11: 171.Google Scholar

56. Lang, EK and Brown, CL. Colorectal metastasis to the liver: Selective chemoembolization. Radiology 1993; 189: 417–422.Google Scholar

57. Stuart, K, Huberman, M, Posner, M, et al. Chemoembolization for colorectal liver metastases [abstract]. Proc Am Soc Clin Oncol 1995; 14 (439): 190.Google Scholar

58. Sanz-Altamira, PM, Spence, LD, Huberman, MS, et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: A phase II trial. Dis Colon Rectum 1997; 40 (7): 770–775.Google Scholar

59. Bavisotto, LM, Patel, NH, Althaus, SJ, et al. Hepatic trans-catheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to the liver: A phase II trial of the Puget Sound Oncology Consortium (PSOC 1104). Clin Cancer Res 1999; 5 (1): 95–109.Google Scholar

60. Salman, HS, Cynamon, J, Jagust, M, et al. Randomized phase II trial of embolization versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer 2002; 2 (3): 173–179.Google Scholar

61. Muller, H, Nakchbandi, V, Chatzisavvidis, I, et al. Repetitive chemoembolization with melphalan plus intraarterial immunochemotherapy with 5-fluorouracil and granulocyte-macrophage colony stimulating factor (GMCSF) as effective first- and second-line treatment of disseminated colorectal liver metastases Hepatogastroenterology 2003; 50 (54): 1919–1926.Google Scholar

62. You, YT, Changchien, CR, Huang, JS, Ng, KK. Combining systemic chemotherapy with chemoembolization in the treatment of unresectable hepatic metastases from colorectal cancer. Int J Colorectal Dis 2006; 21: 33–37.Google Scholar

63. Hong, K, McBride, JD, Georgiades, CS, et al. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol 2009; 20 (3): 360–367. PMID: 19167245Google Scholar

64. Albert, M, Kiefer, MV, Sun, W, et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, Ethiodol, and polyvinyl alcohol. Cancer 2011; 117: 343–352.Google Scholar

65. Nishiofuku, H, Tanaka, T, Matsuoka, M, et al. Transcatheter arterial chemoembolization using cisplatin powder mixed with degradable starch microspheres for colorectal liver metastases after FOLFOX failure; results of a phase I/II trial. J Vasc Interv Radiol 2013; 24: 56–65.Google Scholar

66. Gruber-Rouh, T, Naguib, NNN, Eichler, K, et al. Transarterial chemoembolization of unresectable chemotherapy-refractory liver metastases from colorectal cancer: Long-term results over a 10-year period. Int J Cancer 2014; 134: 1225–1231.Google Scholar

67. Rossi, L, Vakiarou, F, Zoratto, F, et al. Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). Cancer Manag Res 2013; 5: 377–385.Google Scholar

68. Vogl, TJ, Jost, A, Nour-Eldin, NA, et al. Repeated transarterial chemoembolization using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma. Br J Cancer 2012; 106: 1274–1279.Google Scholar

69. Martin, RC, 2nd, Scoggins, CR, Tomalty, D, et al. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: Results of pharmacokinetics and phase I trial. J Gastrointest Surg 2012; 16: 1531–1538.Google Scholar

70. Martin, RC, Joshi, J, Robbins, K, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemicchemotherapy: results of multi-institutional study. Ann Surg Oncol 2011; 18: 192–198.Google Scholar

71. Richardson, AJ, Laurence, JM, Lam, VW. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: Systematic review. J Vasc Interv Radiol 2013; 24: 1209–1217.Google Scholar

72. Narayanan, G, Barbery, K, Suthar, R, et al. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. Anticancer Res 2013; 33: 2077–2083.Google Scholar

Accessibility standard: Unknown

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

Accessibility compliance for the PDF of this chapter is currently unknown and may be updated in the future.